Summary:
Click image to enlargeThis is a Phase 4, randomized, double-blind, placebocontrolled,
multicenter study of topical testosterone
replacement therapy (TRT) in symptomatic hypogonadal
men with increased risk for cardiovascular (CV) disease.
Qualified Participants Must:
• Men whose age is between 45 and 80 years with a history of cardiovascular disease
Qualified Participants May Receive:
$85 per completed onsite visits